H.C. Wainwright raises Annexon stock price target on GBS approval prospects

H.C. Wainwright raised its price target for Annexon Biosciences (ANNX) to $25, citing catalysts like the tanruprubart BLA submission for GBS and ARCHER II readout for vonaprument. The firm values these at $11.70 and $13.60 per share, respectively. ANNX trades at $3.96, down 38% in six months, with a strong balance sheet but high cash burn. Recent Q2 loss was $0.28 per share. Other analysts also raised targets and ratings.

Original reporting
Published Oct 20, 2026, 11:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 12:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ANNX
Bullish
high confidence
Mentioned
$ANNX
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ANNXBullishMed
01

Why it matters

Analyst upgrades and a new $25 price target reflect optimism around upcoming Phase 3 data, potentially driving short‑term buying interest.

02

Market read

The combined analyst upgrades could spark a modest rally in ANNX, with broader biotech sentiment potentially benefiting peers.

03

What to watch

Cash burn of $193 M annually may constrain runway if trial results are delayed.

Relevance 7/10Novelty 6/10Timing: today

Background

Annexon Biosciences is a small-cap biotech developing therapies for Guillain‑Barré syndrome and geographic atrophy.

Company-level read

Ticker impact

$ANNXBullishHigh confidence
Context

H.C. Wainwright raised its price target on Annexon Biosciences to $25 and noted upcoming trial readouts as catalysts.

Expected impact

likely upward pressure as investors price in the higher target and trial expectations

Evidence & confidence

Target increase from $14 to $25 reflects strong belief in trial success; similar upgrades from Citizens and JPMorgan reinforce the bullish view.

Market effects

Positive sentiment may lift other biotech stocks focused on neurology and ophthalmology.

Limited to US-listed biotech sector.

Minimal global impact beyond niche biotech investors.

Counterpoint

The trial readouts remain uncertain; a miss could quickly reverse the price target hike.

Key entities

  • H.C. Wainwright

    Raised price target to $25, maintains Buy rating.

  • Citizens

    Upgraded rating to Market Perform.

  • JPMorgan

    Raised price target to $15, maintains Overweight.

Related articles

$ANNXHigh

Wells Fargo Names Top Pick in Biotechnology Sector

Wells Fargo named Annexon, Inc. its top biotech pick, maintaining an Overweight rating and $27.00 price target. The firm cited the company's ARCHER II trial for vonaprument in generalized myasthenia gravis (GA) as a key catalyst, with a 55% success probability. Annexon has near-term catalysts, including a Q4 2026 data readout and a BLA submission. The company has $213M in cash and a $200M credit facility. Shares are down 16% YTD, underperforming the SPDR S&P Biotech ETF's 29% gain.

$ANNXMed

Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Annexon, Inc. (ANNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts Tanruprubart U.S./EU FORWARD Data in G

$ANNXMed

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. Key updates include ARCHER II trial progress in geographic atrophy and plans for a BLA submission for tanruprubart in Q4 2026. Management projects funding into 2028.

$ANNXMedAI 8/10

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. ARCHER II trial for geographic atrophy enrolled 659 patients, exceeding targets. Tanruprubart for Guillain-Barré syndrome (GBS) is on track for BLA submission in Q4 2026, with positive FORWARD study data. Operations are funded into 2028.